

## ASX ANNOUNCEMENT

### Benitec Completes A\$7.9 million Private Placement

- **A\$7.9M private placement completed to new and existing institutional and sophisticated investors**
- **Share Purchase Plan to raise up to an additional \$3.0M to close on 29 July 2013**
- **Capital raised ensures sufficient funding in place to fund two clinical trials - Phase I/IIa trial in hepatitis C (HCV) and Phase I/IIa trial in drug resistant lung cancer**
- **On track to commence Phase I/IIa HCV trial in 2H CY13 with interim safety and efficacy data expected late CY13/Q1 CY14**

**Sydney Australia, 23 July 2013:** Benitec Biopharma Limited (ASX Code: BLT), today announced that it has completed a private placement of its shares raising A\$7,900,000. Pursuant to the Company's capital raising announcement to the ASX on 6 June 2013, Benitec received additional oversubscriptions under the private placement totalling A\$900,000.

A total of 28,727,273 new fully paid shares post 25:1 consolidation were issued under the private placement, and were the subject of shareholder approval at the Company's General Meeting on 17 July 2013. Included in the placement were 1,498,184 post 25:1 consolidation shares allotted on 14 June 2013. The new fully paid shares were issued at A\$0.011 on a pre consolidation basis and \$0.275 on a post 25:1 consolidation basis, and the shares were placed to several new institutional investors, along with Benitec management and directors and existing sophisticated investors.

Benitec will also raise up to an additional A\$3,000,000 via a share purchase plan (SPP) to existing shareholders on the same terms as the Private Placement, with the closing date for the SPP on 29 July 2013.

Proceeds from the private placement and SPP, together with existing cash, will be used to complete the Company's US-based Phase I/IIa HCV trial, planned to commence in 2H CY13. In addition, Benitec will complete preclinical toxicology, biodistribution and dose-finding studies for Tribetarna its drug resistant non-small cell lung cancer (NSCLC) program, and conduct a European based Phase I/IIa clinical trial in drug resistant NSCLC patients planned to commence in Q4 CY14.

The Company will also use the proceeds to conduct the manufacture of clinical material for a potential second HCV clinical trial (based on outcomes from the first trial), as well as advance business development activities and pre-clinical studies in pipeline programs, and for general working capital.

**For more information please contact:** Dr Peter French | Chief Executive Officer  
Phone: +61 (02) 9555 6986 | [pfrench@benitec.com](mailto:pfrench@benitec.com) | [www.benitec.com](http://www.benitec.com)

**About Benitec Biopharma Limited:** Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com).